Compass generates revenue from real estate commissions, but its profitability depends on how much of that revenue it retains ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new clinical data from two ...

Psychedelic drug developer Compass Pathways is preparing to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression (TRD), after reporting positive ...

Independent computer analysts are on high alert. With the spread of artificial intelligence, the risks to our privacy are ...

IBM and Cobalt Iron are launching Secure Automated Backup with Compass for IBM Cloud customers—a major expansion of the companies’ joint commitment to deliver modern, automated, and highly secure data ...

Investing.com - William Blair reiterated an Outperform rating on Compass Therapeutics (NASDAQ:CMPX) on Thursday as the company reported fourth-quarter earnings and provided a business update. The ...

Compass Therapeutics, Inc. is set to report fourth-quarter and full-year 2025 results on Friday, with investors focused less on the biotech’s expected loss and more on progress toward a potential ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Good morning. I’ve fallen ...

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report ...